Recent Updates
Recently added Catalysts

AZD6234

Phase 3

Obesity | Small Molecules | Metabolic |AstraZeneca PLC|Trials Updated: Nov 9, 2026

AZD6234 development status

Highest phase Phase 3
Registered trials 15 across 1 sponsor since Aug 2022

AZD6234 target and mechanism

ModalitySmall Molecules

Also known as AZD6234 Formulation 1, AZD6234 Formulation 2 (low concentration), AZD6234 Formulation 2, AZD6234 Formulation 3, AZD6234 solution for injection, AZD6234 Formulation 2 (high concentration), Lenbelintide

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials9
Total Enrollment5,229

FDA Designations

No designations recorded

AZD6234 clinical trials

AZD6234 · 9 trials · 12 indications

Phase 3 4Phase 2 3Phase 1 2
NCT07922330A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 DiabetesObesity
NOT YET_RECRUITING330 Analytics
NCT07776509A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes MellitusObesity or Overweight
RECRUITING500 Analytics
NCT07784270A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or OverweightObesity or Overweight
RECRUITING1,500 Analytics
NCT07784725A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes MellitusObesity or Overweight
RECRUITING2,500 Analytics
PHASE3NOT YET_RECRUITING
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
ObesityUnlock trial analytics
PHASE3RECRUITING
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
Obesity or OverweightUnlock trial analytics
PHASE3RECRUITING
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
Obesity or OverweightUnlock trial analytics
PHASE3RECRUITING
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
Obesity or OverweightUnlock trial analytics

Study Endpoints

Primary Endpoints

Percent change in body weight from baseline at Week 64
up to 64 weeks

To evaluate the effect of AZD6234 as compared to placebo in percent body weight change from baseline of treatment.

Number of participants achieving at Least a 5% Reduction in Body Weight From Baseline at Week 64
up to 64 weeks

To evaluate the effect of AZD6234 as compared to placebo in body weight loss of at least 5% from baseline of treatment.

Percent change in body weight from baseline at 68 weeks of treatment
68 weeks

To evaluate the effect of AZD6234 as compared to placebo as an adjunct to incretin-based therapies in percent body weight change

Percent change in body weight from baseline at 68 weeks of treatment.
68 weeks

To evaluate the effect of AZD6234 compared to placebo in percent body weight change

Numbers of participant with Adverse Events (AEs) and Serious adverse events (SAEs) (sub-study 1).
From baseline to Day 141

To assess the safety and tolerability of repeated subcutaneous(SC) doses of AZD6234 compared to placebo.

Numbers of participant with Adverse Events (AEs) and Serious adverse events (SAEs) (sub-study 2).
From baseline to Day 225

To assess the safety and tolerability of repeated SC doses of AZD9550 and AZD6234 in combination with AZD9550 compared to placebo.

Percent change in body weight from baseline at Study Week 26
From baseline to week 26

To determine whether treatment with AZD6234 is superior to placebo for weight loss at Study Week 26

Weight loss ≥ 5% from baseline at Study Week 26
From baseline to week 26

To assess the effect of AZD6234 versus placebo on the proportion of participants with weight loss ≥ 5% from baseline at Study Week 26

Percent change in body weight from baseline to week 26
26 weeks

To determine whether AZD6234 is superior to placebo for weight loss

Weight loss ≥ 5% from baseline weight to week 26
26 weeks

To determine whether AZD6234 is superior to placebo in participants with weight loss ≥ 5% from baseline

PK parameters AUCinf
Day 0 through Day 56

To compare the plasma PK of separate single SC doses of AZD9550 and AZD6234 in participants with severe and moderate hepatic impairment with matched controls with normal hepatic function

PK parameters AUClast
Day 0 through Day 56

To compare the plasma PK of separate single SC doses of AZD9550 and AZD6234 in participants with severe and moderate hepatic impairment with matched controls with normal hepatic function

PK parameters Cmax
Day 0 through Day 56

To compare the plasma PK of separate single SC doses of AZD9550 and AZD6234 in participants with severe and moderate hepatic impairment with matched controls with normal hepatic function

AUClast
Day 1 to Day 36

Area under plasma concentration-time curve from time zero to the last measurable concentration

AUCinf
Day 1 to Day 36

Area under plasma concentration-time curve from zero to infinity

Cmax
Day 1 to Day 36

Maximum observed plasma concentration

Secondary Endpoints

Number of participants achieving at Least a 10% Reduction in Body Weight From Baseline at Week 64
up to 64 weeks
Change in waist circumference from baseline
up to 64 weeks
Absolute change in weight from baseline
up to 64 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
AZD6234 Higher Target-DoseEXPERIMENTALParticipants will receive AZD6234 with dose titration to the higher target dose, followed by a safety follow-up period.
AZD6234 Lower Target-DoseEXPERIMENTALParticipants will receive AZD6234 with dose titration to the lower target dose, followed by a safety follow-up period.
PlaceboPLACEBO_COMPARATORParticipants will receive matching placebo with dose titration according to the protocol, followed by a safety follow-up period.
AZD6234EXPERIMENTALAZD6234
AZD6234 Dose 1EXPERIMENTALAZD6234 Dose 1
AZD6234 Dose 2EXPERIMENTALAZD6234 Dose 2
AZD6234 (sub-study 1)EXPERIMENTALParticipants will receive subcutaneous injection of AZD6234 on Day 1 and continue for 16 weeks.
Placebo (sub-study 1)PLACEBO_COMPARATORParticipants will receive subcutaneous injection of matched volume of placebo on Day 1 and continue for 16 weeks.
AZD9550(sub-study 2 Cohort A)EXPERIMENTALParticipants will receive subcutaneous injection of AZD9550 on Day 1 and continue for 28 weeks.
Placebo (sub-study 2 Cohort A)PLACEBO_COMPARATORParticipants will receive subcutaneous injection of matched volume of placebo on Day 1 and continue for 28 weeks.
AZD6234 in combination with AZD9550 (sub-study 2 Cohort B)EXPERIMENTALParticipants will receive subcutaneous injection of AZD6234 and AZD9550 on Day 1 and continue for 28 weeks.
Placebo (sub-study 2 Cohort B)PLACEBO_COMPARATORParticipants will receive subcutaneous injection of matched volume of placebo on Day 1 and continue for 28 weeks.
Placebo for AZD6234PLACEBO_COMPARATORWeekly SC injections of matching placebo
Arm 1EXPERIMENTALDose 1
Arm 2EXPERIMENTALDose 2
Arm 3EXPERIMENTALDose 3
Arm 4PLACEBO_COMPARATORPlacebo - Dose matched with each Experimental arm
Group 1EXPERIMENTALParticipants with severe hepatic impairment (CP Class C, score of 10 to 15).
Group 2EXPERIMENTALParticipants with moderate hepatic impairment (CP Class B, score of 7 to 9).
Group 3EXPERIMENTALParticipants with normal hepatic function matched on a group level regarding sex, age, and BMI to the participants with hepatic impairment.
Group 4 (optional)EXPERIMENTALSubjects with moderate renal impairment will receive a single subcutaneous dose of AZD6234 under fasted conditions
Group 5 (optional)EXPERIMENTALSubjects with mild renal impairment will receive a single subcutaneous dose of AZD6234 under fasted conditions

Interventions

NameTypeDescription
AZD6234DRUGadministered once weekly.
PlaceboDRUGMatching placebo administered once weekly.
LenbelintideDRUGIMP injected subcutaneously, once a week.
AZD9550DRUGParticipants will receive a subcutaneous injection weekly
PloceboDRUGParticipants will receive a subcutaneous injection weekly
AZD6234 in combination with AZD9550DRUGParticipants will receive a subcutaneous injection weekly
Placebo to matchDRUGWeekly SC injections of matching placebo
Placebo comparatorDRUGPlacebo matching IMP dose injected subcutaneously, once a week.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites34

Inclusion Criteria: * Aged 18 years or older at the time of signing informed consent. * Body mass index: * at least 28 kg/m²; or * at least 24 kg/m² and less than 28 kg/m² with at least one protocol-defined weight-related comorbidity, including type 2 diabetes mellitus, hypertension, dyslipidaemia,...

Countries:ChinaIndiaUnited StatesArgentinaBrazilCanadaDenmarkIsraelJapanSwedenTurkey (Türkiye)United KingdomAustraliaChileGermanyHungaryPolandSlovakiaSouth KoreaSpainTaiwanBulgariaCzechiaFranceItaly
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 9, 2026NCT07776509lastUpdatePostDate: changed
LOWNov 9, 2026NCT07776509lastUpdatePostDate: changed
LOWNov 6, 2026NCT07922330NEW_TRIAL: changed
LOWNov 6, 2026NCT07922330NEW_TRIAL: changed
MEDIUMNov 2, 2026NCT06595238TRIAL_REMOVED: changed
MEDIUMNov 2, 2026NCT06595238TRIAL_REMOVED: changed
MEDIUMNov 2, 2026NCT06595238TRIAL_REMOVED: changed
MEDIUMOct 30, 2026NCT07784725lastUpdatePostDate: changed
MEDIUMOct 30, 2026NCT07784725lastUpdatePostDate: changed
MEDIUMOct 28, 2026NCT07784270primaryCompletionDate: changed
MEDIUMOct 28, 2026NCT07784270primaryCompletionDate: changed
MEDIUMOct 25, 2026NCT06851858TRIAL_REMOVED: changed
MEDIUMOct 25, 2026NCT06851858TRIAL_REMOVED: changed
MEDIUMOct 25, 2026NCT06851858TRIAL_REMOVED: changed
LOWOct 22, 2026NCT07546760lastUpdatePostDate: changed
LOWOct 22, 2026NCT07546760lastUpdatePostDate: changed
LOWSep 29, 2026NCT07017179Enrollment: 14 → 16
LOWSep 29, 2026NCT07017179Enrollment: 14 → 16

Frequently asked questions about AZD6234

What is AZD6234?

AZD6234 is an investigational small molecule drug developed by AstraZeneca for metabolic conditions, including obesity, overweight, and related disorders. It is being studied in adults with obesity or overweight, including people who also have type 2 diabetes, and in participants with hepatic impairment. AZD6234 is not yet approved and remains in clinical development.

What is AZD6234 used for in obesity and overweight?

AZD6234 is being developed to manage weight in adults who are obese or overweight, including participants who may or may not also have type 2 diabetes. AstraZeneca is also studying it in people with overweight or obesity and type 2 diabetes who are on a stable dose of a GLP-1 receptor agonist.

Who makes AZD6234?

AZD6234 is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is running the clinical program for AZD6234 across obesity, overweight, hepatic impairment, and related metabolic indications, including studies in China, India, and the United States.

What phase is AZD6234 in?

AZD6234 is in Phase 2 development overall, with a Phase 3 trial also registered. The Phase 3 study in obesity and overweight is not yet recruiting, while Phase 2 studies include a completed trial in overweight or obesity with type 2 diabetes and an active platform study in Chinese participants. AZD6234 is investigational and not approved.

What clinical trials is AZD6234 in?

AZD6234 trials include NCT06851858, a completed Phase 2 study in overweight or obesity with type 2 diabetes on a stable GLP-1 receptor agonist dose; NCT07017179, an active Phase 2 platform study in Chinese participants with obesity or overweight; NCT07546760, a recruiting Phase 1 hepatic impairment study; and NCT07922330, a Phase 3 weight management study not yet recruiting.

Is AZD6234 the same as AZD6234 Formulation 1 or AZD6234 solution for injection?

Yes. AZD6234 Formulation 1, AZD6234 Formulation 2 (low concentration), AZD6234 Formulation 2, AZD6234 Formulation 3, and AZD6234 solution for injection all refer to the same investigational drug, AZD6234, developed by AstraZeneca. These names describe different formulations or presentations of the compound studied in its clinical program.